Lisa is a stock analyst with nearly 25 years of investment research experience. She earned a MBA in Finance from the University of Chicago in 1987 and began her career in investment research that same year as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of director of financial analysis.
During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy and other Fortune 1000 companies. In 2000, Lisa left to become director of investor Relations for a NYSE-listed REIT, serving in that position until the REIT was acquired. Since then, Lisa has worked as a stock analyst for independent research firms, investment newsletters and financial websites.
Analyst Articles
With all of the media buzz that surrounds next-generation smartphones and their new apps, it’s hard for investors to get too excited about good old-fashioned telecoms these days. That’s a shame, since these companies can be a rich source of dividends for income investors. Many pay 5% yields, and some… Read More
Last summer, when Netflix (Nasdaq: NFLX) was messing with its pricing plans, alienating its customers in the process, I spotted a clear opening for rival Coinstar (Nasdaq: CSTR), which runs a kiosk-based DVD distribution system. As I wrote then: “Thanks to Netflix, Coinstar’s DVD business will thrive… Read More
The story was picked up by the major news sources as a “cute” human interest feature. You might have seen the headlines like “How a Secretary Made and Gave Away $7 Million.” But for me, this wasn’t some light news piece. This was a story that resonated… Read More
In the past seven years, Home Depot (NYSE: HD) has bought back a whopping 600 million shares. That’s really impressive until you realize many of the shares were bought back right when the stock was trading at a… Read More
As the market has crawled ever higher during the past three years, a clear theme has emerged: When the market slumps, investor pessimism gets carried to extremes; and when the market posts a strong rally, things are not as solid as they appear. Read More
Many investors have rejected emerging markets, and I can’t say I blame them. As a group, emerging markets really went sour in 2011, dropping nearly 19% and trailing the S&P 500’s 2% gain by about 21%. Still, I urge those who feel these markets… Read More
I’ve noted on a few occasions that investing in shares of biotech companies is quite challenging for the average investor. In this case, as I suggested a few weeks ago, a biotech fund may be the best choice for some, since it reduces the… Read More
While the mainstream financial media chases every conceivable Facebook angle ahead of its initial public offering (IPO), which is expected sometime in May, it’s important not to get lost in the frenzy. About $5 billion worth of… Read More
Some positive signs are emerging from the banking sector, particularly among the regional banks -- where I've found yields of up to 8.0%. Read More
For companies that carry a huge load of debt, there is no room for error. Cash-flow targets need to be met simply to assure investors that funds will be in place to meet future bond redemptions. If… Read More
